• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 4, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Frequency and outcomes of new suspicious lesions on breast MRI in neoadjuvant therapy

Bioengineer by Bioengineer
May 7, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 7, 2019–During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The study was conducted to determine the frequency and outcomes of new suspicious lesions on breast MRI arising during neoadjuvant chemotherapy.

A retrospective database review found a total of 419 breast MRI examinations performed in 297 women to evaluate response to neoadjuvant chemotherapy. After exclusions for reasons including a lack of baseline pretreatment MRI for comparison, the final study cohort consisted of 28 MRI examinations (7%) with new suspicious findings.

All cases included in the study were assessed as BI-RADS 4. Twenty-five cases had either tissue diagnosis or adequate imaging follow-up to establish a diagnosis of the new suspicious findings on breast MRI. Of these 25 cases, 44% were proven benign at percutaneous biopsy, 20% at surgical pathology, and 36% were assessed benign based on follow-up imaging of 2 years or longer. That is, for all 25 cases the cancer yield for new suspicious lesions was 0%.

Results suggest that new suspicious finding on breast MRI which occur during neoadjuvant therapy are highly unlikely to signify a new malignancy, although the authors encourage further study to confirm whether biopsy may be safely avoided in these circumstances.

“We found that new suspicious lesions on MRI are not rare, occurring 7% of the time,” Donna Eckstein, MD, author of the study said. “Nearly all of these new lesions arose while the index tumor showed treatment response on MRI, and none of these new lesions were malignant. Larger studies across facilities are needed to confirm whether biopsy may be safely averted in these scenarios.”

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/neoadjuvant-therapy-lesions-breast-mri.aspx

Tags: Breast CancercancerDiagnosticsHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Adding Immunotherapy to Chemo and Bevacizumab Extends Survival in Recurrent Cervical Cancer

Adding Immunotherapy to Chemo and Bevacizumab Extends Survival in Recurrent Cervical Cancer

October 4, 2026
Persistent Emotional Distress Tracks With Poorer Survival in Lung Cancer Patients Undergoing Neoadjuvant Therapy and Surgery

Persistent Emotional Distress Tracks With Poorer Survival in Lung Cancer Patients Undergoing Neoadjuvant Therapy and Surgery

October 4, 2026

Shortened Liver MRI Protocol Shows Strong Accuracy for Spotting Tumor Return After Ablation

October 4, 2026

Gamma Delta T Cells Blur the Line Between Innate and Adaptive Immunity

October 4, 2026
Please login to join discussion

POPULAR NEWS

  • Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    29 shares
    Share 12 Tweet 7
  • Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

    29 shares
    Share 12 Tweet 7
  • Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

    29 shares
    Share 12 Tweet 7
  • New Scale Measures How Ready Nurse Educators Really Are for the AI Era

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.